TransMedics Group Inc (TMDX) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Total Cash From Operating Activities Chart for TransMedics Group Inc
TransMedics Group Inc (TMDX) operating cash flow for FY2025 was USD 192.8M, a 295.1% change from FY2024. TransMedics Group Inc's operating cash flow moved from USD -16.3M in 2006 to USD 192.8M in 2025 over 19 years.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.45B
- Implied Share Price
- $70.74
- Enterprise Value
- $4.08B
- Revenue (TTM)
- $668.47M
- EBITDA
- $115.63M
- Profit Margin
- 22.69%
- Trailing P/E
- 18.33
- Forward P/E
- 52.36
- Price/Book (MRQ)
- 12.44
- Price/Sales (TTM)
- 3.67
- EV/EBITDA
- 36.40
- EV/Revenue
- 7.67
- Dividend Yield
- —
- Book Value
- $14.96
- Free Cash Flow (FY2025)
- $133.59M
- Free Cash Flow Yield
- 5.45%
Snapshot as of 25th October 2026 — not point-in-time controlled, may lag the live market by a few days.